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Purpose: To determine whether patients with isolated primary open-angle glaucoma (POAG) have evidence of
chromosomal copy number alterations.
Methods: Twenty-seven Caucasian and African-American POAG patients and 12 ethnically matched controls were
carefully screened for possible glaucoma and tested for chromosomal copy number alterations using high resolution array
comparative genomic hybridization.
Results: No POAG patient had evidence of chromosomal copy number alterations when compared to normal ethnically
matched controls. Additionally, there was no evidence of somatic mosaicism in any tested POAG patient.
Conclusions: Chromosomal deletions and/or duplications were not detected in POAG patients as compared to controls.
Other chromosomal imbalances such as translocations, inversions, and some ploidies cannot be detected by current array
comparative genomic hybridization technology, and other nuclear genetic, mitochondrial abnormalities, or epigenetic
factors cannot be excluded as a possible contributing factor to POAG pathogenesis.
Glaucoma is one of the leading causes of blindness
worldwide [1] with a prevalence of over 2% in individuals
older than 40 years [2]. Primary open-angle glaucoma
(POAG) is the most common type of glaucoma in Western
countries and has risk factors that include elevated intraocular
pressure (IOP) and age [3], but these factors do not predict the
presence or degree of visual loss [4]. Up to half of all patients
with POAG have a positive family history, and the risk of
POAG is increased three to nine times in first-degree relatives
of POAG patients [2,5]. These observations suggest that
genetic factors contribute to POAG [1,6,7].
Currently, 14 chromosomal loci are linked to POAG by
the Human Genome Organization. Thus far, only three genes
associated with POAG have been identified within these loci
including myocilin [8], optineurin [9], and WD repeat domain
36 (WDR36) [10]. However, mutations in these three genes
are present in less than 5% of POAG patients [11]. Over 20
other gene variants have been associated with the disorder, but
in general, these loci have been identified from linkage
analysis of family data sets often without corroboration by
other investigators or in other populations. Therefore, the
cause of the genetic risk for the occurrence of POAG remains
largely unknown.
Correspondence to: Khaled K. Abu-Amero, Ph.D., Ophthalmic
Genetics Laboratory, Department of Ophthalmology, College of
Medicine, King Saud University, PO Box 245, Riyadh, 11411, Saudi
Arabia; Phone: +96614786100; FAX: +96614775742; email:
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Several chromosomal aberrations have been reported to
cause glaucoma, but in general, glaucoma has been associated
with an obvious genetic syndrome in these patients [12,13].
To our knowledge, no study has investigated chromosomal
copy number variations in patients with isolated POAG.
Therefore, we examined possible chromosomal copy number
changes in POAG patients using high resolution array
comparative genomic hybridization (array CGH) technology.
METHODS
Patients and controls: Patients were selected from the
Glaucoma Clinic at Wills Eye Hospital (Philadelphia, PA)
after examination by a glaucoma specialist and after obtaining
informed consent approved by the Wills Institutional Review
Board. This research adhered to the tenets of the Declaration
of Helsinki, and all patients and controls signed an informed
consent approved by the Wills Eye Hospital Institutional
Review Board.
Patients were eligible for inclusion in this study if they
met standard clinical criteria for POAG [14-16] including age
greater than 40 years, IOP greater than or equal to 21 mmHg
in at least one eye before treatment, normal-appearing anterior
chamber angles bilaterally on gonioscopy, and optic nerve
injury characteristic of POAG (with narrowed or absent rim,
asymmetric cupping of the optic discs, and static visual fields
compatible with optic disc appearance and with glaucoma).
Exclusion criteria included historical, neuroimaging, or
biochemical evidence of another possible optic neuropathic
process affecting either eye, significant visual loss in both
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eyes not associated with glaucoma, or choosing not to
participate.
All control subjects had full ophthalmologic
examinations and static perimetry. Each had IOPs below 21
mmHg and symmetry in the two eyes, normal anterior
Figure 1. Array CGH result for internal control. As an internal quality
control for the array CGH procedure, control DNA was hybridized
against POAG DNA of the opposite sex (ratio of +1 with regard to
chromosome X for XX POAG and XY control).
chambers, optic discs that were normal and symmetric in
appearance, entirely normal static perimetry (both eyes), and
no prior history of glaucoma. All patients and controls had
Humphrey Swedish interactive threshold algorithm (SITA)
achromatic static perimetry, stimulus III, 24–2 (Humphrey
Field Analyzer II; Carl Zeiss Meditec Inc., Dublin, CA).
Array CGH technique: Blood was collected in acid-citrate-
dextrose (ACD) tubes, and DNA was extracted using a Qiagen
Autopure LS instrument (Qiagen, Valencia, CA) following
the manufacturer’s recommended procedure. To detect
chromosomal rearrangements, 2 μg of POAG patient genomic
DNA was competitively hybridized with 2 μg of ethnically
matched control DNA (as a reference sample) on an Agilent
Human Genome CGH 244A Oligo Microarray Kit (Agilent
Technologies Inc., Santa Clara, CA), which has an average
probe spacing across the human genome of 6.4 Kb. Briefly,
50 μl of DNA from POAG patients and controls was digested
using 50 units of Alu1 (Roche, Mannheim, Germany) and 50
units of Rsa1 (Roche) restriction enzymes in a 100 μl volume
with 10 μl of 10X Promega Buffer C. Digestions were
performed for 2 h at 37 °C. Digested samples were purified
using QIAprep Spin Miniprep columns (Qiagen) and eluted
according to the manufacturer's instructions. Samples were
then analyzed using the Agilent 2100 Bioanalyzer with the
DNA 7500 LabChip Kit and DNA 7500 Software Script
(Agilent) as per the manufacturer’s instructions. Alu1/Rsa1
digested DNA samples were labeled using the BioPrime
Array CGH Labeling Kit (Invitrogen, Carlsbad, CA)
according to the manufacturer's protocol. POAG patient and
control DNA samples were systematically labeled with Alexa
Fluor 555 and 647, respectively.
Labeled products of each sample and control DNA were
purified using QIAprep Spin Miniprep columns (Qiagen),
mixed together, and checked on the Agilent 2100 Bioanalyzer
(Agilent) to evaluate the Alexa Fluor 555 integration into the
DNA samples. The following hybridization blocking reagents
were added to the purified Alexa Fluor 555 and 647 labeled
samples: 50 μg Cot-1 DNA (Invitrogen) and 50 μl of 10X
control targets (Agilent). The volume was brought to 250 μl
with double-distilled H2O, and 250 μl of 2X hybridization
buffer (Agilent) was added. The hybridization mixture was
then denatured at 100 °C for 3 min in a water bath. Samples
were immediately transferred to a 37 °C water bath for 30 min
to allow pre-annealing of the blocking agents to the labeled
sample. Samples were centrifuged for 5 min at 16,000x g and
immediately applied to the Agilent Human Genome CGH
244A Oligo Microarray Kit as per the manufacturer's
recommendations. Hybridizations were performed at 65 °C
for 42 h.
Microarrays were disassembled in Agilent wash buffer-1
at room temperature (RT), transferred to a slide holder, and
incubated for 5 min with stirring in the Agilent wash buffer-1
at RT. The second washing step was performed for 1 min in
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wash buffer-2 at 37 °C. The third and fourth washing steps
were done with acetonitrile (Fisher Scientific, Fair Lawn, NJ)
and stabilization solutions (Agilent) for 1 min and 30 s at RT,
respectively. Microarray slides were immediately scanned in
the Agilent DNA Microarray Scanner using the default
settings.
Data analysis was performed by Agilent Feature
Extraction 9.1 and CGH Analytics 3.4 (Agilent). Log2
expression ratios were computed and normalized using CGH
Analytics 3.4 software. Putative chromosome copy number
changes were defined by intervals of three or more adjacent
probes with log2 ratios suggestive of a deletion or duplication
when compared with the log2 ratios of adjacent probes. The
quality-weighted interval score algorithm (ADM2) was used
to compute and assist in the identification of aberrations for a
given sample.
As an internal quality control measure, DNA from
Caucasian patients were mixed with DNA from Caucasian
controls of the same and opposite sex and co-hybridized to the
244K chip (Figure 1). The same was done for POAG patients
and controls of African American ethnicity.
RESULTS
Clinical characteristics of the 27 POAG patients included in
this study are detailed in Table 1. Patient sex (15 males and
12 females) and ethnicity (14 Caucasian and 13 African-
American) were similar to that of the 12 controls, which were
carefully screened for presence of POAG or other optic
neuropathies (5 males and 7 females; 9 Caucasian and 3
African-American). The mean age of patients (70.7±10.8
years) was somewhat greater than that of controls (61.1±10.8
years).
The signal ratio of each patient compared to a
simultaneously tested control (patient-cy3/control-cy5)
documented the absence of chromosomal copy number
variations in any patient. No POAG patient had evidence of
somatic mosaicism. Representative images of array CGH
results are shown in Figure 2.
DISCUSSION
The 27 patients reported here met rigorous clinical criteria for
definite POAG [14-16] with elevated IOP, normal anterior
chamber, and evidence on the fundoscopic exam and visual
fields of glaucomatous optic nerve damage. By clinical
criteria, they did not have evidence of other types of glaucoma
or alternative causes of optic nerve injury. None had
dysmorphism or an obvious genetic syndrome. They were
compared to 12 controls in which POAG and other evidence
of optic nerve damage were carefully excluded.
High resolution array CGH used here provides
quantitative information about the level of chromosome gain
or loss such as regions with a high level amplification or high
magnitude deletion and will recognize a chromosomal
duplication or deletion of a size greater than or equal to 6 Kb.
This technique did not detect any chromosomal copy number
variations of this size in POAG patients or controls. These
results indicate that it is very unlikely that chromosomal
deletions or duplications are universally responsible for
isolated POAG. Because of the relatively small sample size,
it remains possible that chromosomal aberrations might be
present in a portion of patients with isolated POAG. More
patients from multiple centers and various ethnicities would
need to be examined to make a general statement about the
absolute absence of chromosomal copy number variations in
the setting of POAG. No comment can be made about other
chromosomal imbalances such as translocations, inversions,
and some ploidies because these cannot be detected by current
array CGH technology.
These negative results stand in contrast to reports of
chromosomal anomalies causing glaucoma in association
with a variety of genetic syndromes and abnormalities of
globe development. For example, several chromosomal
anomalies have been reported to cause the Axenfeld-Rieger
syndrome (OMIM 602482) with variable ocular dysgenesis
associated with short height, stunted development of mid-
facial features, and mental deficiencies. These anomalies
include distal deletions of chromosome 6p [12], duplications
[17], balanced translocations [18], and unbalanced
translocations [19], but they are all associated with abnormal
development of the anterior segment and early onset
glaucoma [20,21]. Similarly, one reported patient was
documented to have partial trisomy of 7q and partial
Figure 2. Array CGH results for POAG patients versus controls.
Chromosomes shown were chosen randomly as representative of all
chromosomes and in all POAG patients tested. In the image, A
indicates Chromosome 1; B indicates Chromosome 13; C indicates
Chromosome 15; and D indicates Chromosome 18. When control
DNA was hybridized against POAG DNA, a signal ratio of zero (0)
was obtained, indicating the absence of chromosomal copy number
alterations.
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monosomy of 15q, and the Silver-Russell phenotype (OMIM
180860; low birth weight, delayed maturation, facial
dysmorphism, clinodactyly, ivory epiphyses, etc.) with
congenital glaucoma [13] while another had a balanced
translocation t(9/17)(q34.1;q25) and the Nail-Patella
Syndrome (OMIM 161200; dysplasia of the nails, absent or
hypoplastic patellae, and a low frequency of glaucoma and
ocular hypertension) [22]. Several reported patients with early
onset glaucoma and genetic syndromes lack a firm genetic
diagnosis [23,24], and micro-anomalies of chromosomes
remain possible in some of these patients. The cohort reported
here had isolated POAG beginning in late adult life without
ocular malformations, dysmorphic features, or other evidence
of genetic syndromes, and to date, no such patient has been
reported to have an associated chromosome aberration.
In summary, we used high resolution array CGH to
evaluate a group of patients with isolated POAG and found
no evidence of chromosomal copy number variations.
Therefore, neither autosomal genetics [11] nor chromosomal
deletions/duplications currently provide a complete
explanation for the substantial familial association widely
recognized in POAG [2,5]. Although unrecognized genetic or
epigenetic factors remain possible, POAG patients do have a
variety of mitochondrial [25] and metabolic [26]
abnormalities that might put the optic nerve at risk. In this
regard, POAG may have certain similarities to Leber
hereditary optic neuropathy, another spontaneous optic
neuropathy with no obvious autosomal or chromosomal [27]
cause that also is associated with mitochondrial abnormalities
[28-30].
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